A combination of trastuzumab, pertuzumab and docetaxel was able to partially overcome trastuzumab resistance and extend survival of patients with metastatic HER2-positive breast cancer from 15 (trastuzumab alone) to 56.5 months [37]. This evidence concerns the gene ERBB2 and breast carcinoma.